A Comparison of Mycophenolate Mofetil with Ciclosporine for the Treatment of Chronic Plaque-Type Psoriasis

被引:13
|
作者
Beissert, Stefan [1 ,5 ]
Pauser, Sylvia [1 ]
Sticherling, Michael [2 ,3 ]
Frieling, Uta [1 ]
Loske, Klaus-Dieter [1 ]
Frosch, Peter J. [4 ]
Haase, Ingo [5 ]
Luger, Thomas A. [1 ]
机构
[1] Univ Munster, Dept Dermatol, DE-48149 Munster, Germany
[2] Univ Leipzig, Dept Dermatol, Leipzig, Germany
[3] Univ Erlangen Nurnberg, Erlangen, Germany
[4] Klinikum Dortmund GmbH, Dortmund, Germany
[5] Univ Cologne, Cologne, Germany
关键词
Psoriasis; clinical study; Immunosuppression; T cells; QUALITY-OF-LIFE; CONSENSUS CONFERENCE; CYCLOSPORINE NEORAL(R); SAFETY; METHOTREXATE; EFFICACY; THERAPY; ACID; MULTICENTER; DISABILITY;
D O I
10.1159/000226134
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Aims: To compare the efficacy of ciclosporine (CsA) versus mycophenolate mofetil (MMF) in psoriasis, a randomized trial was conducted. Methods: A prospective multicenter randomized open-label clinical trial was performed to compare two parallel groups of patients with chronic plaque psoriasis undergoing different treatments. Therefore, a total of 54 patients with psoriasis were randomly assigned to treatment with either CsA (2.5 mg/kg body weight) or MMF (2 g daily) for 12 weeks, and the drug doses were adjusted according to response. The psoriasis area and severity index (PASI) was used to assess the clinical severity of psoriasis. The primary outcome of this trial was the time to disease relapse. Safety, PASI scores and psoriasis disability index (PDI) were assessed as secondary outcome. Results: There was no difference in time to disease relapse between the two groups. After 12 weeks of treatment, the mean PASI score (+/- SD) decreased from 24.6 +/- 11.1 to 6.6 +/- 7.3 in the CsA group (n = 27) and from 22.4 +/- 9.2 to 10.6 +/- 6.7 in the MMF group (n = 27; p = 0.02). The side effects, time to remission and PDI were similar in both groups. Conclusions: After 12 weeks, CsA demonstrated a significantly superior efficacy in psoriasis compared to MMF. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:126 / 132
页数:7
相关论文
共 50 条
  • [1] Topical application of mycophenolate mofetil in plaque-type psoriasis
    Wohlrab, J
    Jahn, K
    Plaetzer, M
    Neubert, R
    Marsch, WC
    BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (06) : 1263 - 1264
  • [2] Atorvastatin for the Treatment of Plaque-Type Psoriasis
    Faghihi, Toktam
    Radfar, Mania
    Mehrabian, Zohre
    Ehsani, Amir Hoshang
    Hemami, Mohsen Rezaei
    PHARMACOTHERAPY, 2011, 31 (11): : 1045 - 1050
  • [3] Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil
    Grundmann-Kollmann, M
    Mooser, G
    Schraeder, P
    Zollner, T
    Kaskel, P
    Ochsendorf, F
    Boehncke, WH
    Kerscher, M
    Kaufmann, R
    Peter, RU
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (05) : 835 - 837
  • [4] Barrier repair in chronic plaque-type psoriasis
    Goon, ATJ
    Yosipovitch, G
    Chan, YH
    Goh, CL
    SKIN RESEARCH AND TECHNOLOGY, 2004, 10 (01) : 10 - 13
  • [5] Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis
    Akhyani, M.
    Chams-Davatchi, C.
    Hemami, M. R.
    Fateh, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 (12) : 1447 - 1451
  • [6] Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin
    Pedraz, J
    Dauden, E
    Delgado-Jiménez, Y
    García-Río, I
    García-Díez, A
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2006, 20 (06) : 702 - 706
  • [7] Plaque-type psoriasis inhibitors
    Shobeiri, Saeideh Sadat
    Khorrami, Motahareh
    Sankian, Mojtaba
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 101
  • [9] Infliximab monotherapy in the treatment of plaque-type psoriasis.
    Gottlieb, AB
    Chaudhari, U
    Romano, P
    Mulcahy, LD
    Dooley, LT
    Baker, DG
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S383 - S383
  • [10] Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis
    Saraceno, Rosita
    Bavetta, Mauro
    Zangrilli, Arianna
    Chiricozzi, Andrea
    Potenza, Concetta
    Chimenti, Sergio
    Chimenti, Maria Sole
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (09) : 1325 - 1334